Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 17, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment...
-
Dec 20, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Abbreviated New Drug Application (ANDA) disputes regarding Injectafer® (ferric carboxymaltose) have now been settled St. Gallen, Switzerland, and...
-
Dec 14, 2021
Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron...
-
Dec 14, 2021
Melbourne, 14 December 2021 – CSL Limited (ASX:CSL) and its vaccine business, Seqirus, today reaffirms a strong commitment to accelerating its proprietary next-generation self-amplifying mRNA...
-
Nov 16, 2020
16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...